Xiaofei Li

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 520 citations

Medicine, Pathology, Gefitinib Versus Vinorelbine +8

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue, Shidong Xu, Qun Wang et al. · The Lancet Respiratory Medicine · 2018 · 288 citations

Medicine, Pathology, Erlotinib Versus Vinorelbine +8

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · Journal of Clinical Oncology · 2020 · 261 citations · Full text

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

Junjie Xi, Wen‐Zhao Zhong, Weimin Mao et al. · Journal of Thoracic Oncology · 2018 · 72 citations

Oncology, Adjuvant Trial, Adjuvant Gefitinib Therapy +9

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Si‐Yang Liu, Hua Bao, Qun Wang et al. · Nature Communications · 2021 · 70 citations · Full text